Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Phase 3 Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Recently Diagnosed Stage 3 Type 1 Diabetes (T1D)

NCT07088068 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07088068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07088068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Phase 3 Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Recently Diagnosed Stage 3 Type 1 Diabetes (T1D)
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Recruiting
Start date
August 6, 2025
Completion date
December 12, 2028
Enrollment
723 (estimated)
Sites
202

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus